Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ATRC
vs
S&P 500
ATRC
S&P 500
Over the past 12 months, ATRC has significantly outperformed S&P 500, delivering a return of +62% compared to S&P 500's +12% growth.
Stocks Performance
ATRC vs S&P 500
Performance Gap
ATRC vs S&P 500
Performance By Year
ATRC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
AtriCure Inc
Glance View
AtriCure makes medical devices used by heart surgeons to treat atrial fibrillation and related heart rhythm problems. Its products include surgical ablation tools that create controlled scar lines in the heart tissue, plus systems used to remove or close off the left atrial appendage, a part of the heart linked to stroke risk in some patients. The company sells mainly to hospitals and cardiac surgery teams. The business makes money by selling equipment and disposable components that surgeons use during procedures. Some products are capital devices installed in hospitals, while others are single-use tools and accessories tied to each operation. That mix gives AtriCure a steady stream of repeat sales after a hospital adopts its systems. What sets AtriCure apart is its narrow focus on surgical treatment for heart rhythm disorders rather than general cardiology. It sits between drug therapy and open-heart surgery, giving surgeons specialized tools for patients who need a procedural approach. In simple terms, AtriCure earns its place by supplying the devices that help doctors treat difficult arrhythmia cases in the operating room.